Medpace
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.www.medpace.com
5
MENTIONS
2
EPISODES
2
PODCASTS
Search complete. 5 mentions across 2 episodes found for "Medpace".
Sep 2, 2026
Ryan HendersonHOST
I just – for me, it's – I would have no way of knowing – whether or not something could come along that would displace them uh what what does the competitive set look like i really don't know i would have i would have had a hard time telling like could they win those lawsuits that they won you know if they don't that's a good point it's going to be hurtful for the business so yeah uh it's probably a pass for me what about you
Brett SchaeferHOST
Yeah, I put it in the same category as the Medpace, Illumina, there's others, Brooker, even Thermo Fisher and Danaher.
Brett SchaeferHOST
I think they all kind of are in the same area.
Brett SchaeferHOST
Obviously, tennis genomics is much more high risk than some of those other players.
Dan SferaHOST
Now, the central thesis.
Dan SferaHOST
The first thesis, like I said, the first document where this is coming from is IQVIA, Icon, Medpace, Fortrea, Thermo Fisher, and Charles River Labs.
Dan SferaHOST
It's their second quarter earnings calls.
Dan SferaHOST
The next document is J.P. Morgan's report on biopharma venture funding, licensing, mergers and acquisitions, and the all-important and getting healthier initial public offerings market.
15 MINS LATER
Dan SferaHOST
IQVIA reported three billion dollars of net new bookings during the last quarter.
Dan SferaHOST
Icon, three billion as well.
Dan SferaHOST
Medpace, which is a much smaller CRO, seven hundred and ninety-six million dollars of net awards.
Dan SferaHOST
Those are all an increase of about twenty to thirty percent from the previous quarter to quarter, if you compare quarter two with quarter two of twenty-twenty five.